Ampio Pharmaceuticals (AMPE) 10-Q 6 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 01, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	AMPE
Entity Registrant Name	AMPIO PHARMACEUTICALS, INC.
Entity Central Index Key	1,411,906
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		52,016,432

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 11,114,654	$ 15,998,392
Receivable from Aytu BioScience, Inc.		38,451
Prepaid expenses	432,709	321,574
Prepaid research and development - related party (Note 6)	143,802	143,802
Current assets of discontinued operations (Note 7)		12,726,203
Total current assets	11,691,165	29,228,422
Fixed assets, net (Note 2)	8,882,087	9,187,620
Equity investment in Aytu BioScience, Inc.	959,734
Long-term portion of prepaid research and development - related party (Note 6)	287,603	323,553
Deposits	33,856	33,856
Other assets of discontinued operations, net (Note 7)		11,645,142
Total assets	21,854,445	50,418,593
Current liabilities
Accounts payable	2,210,872	1,804,369
Accrued compensation	1,040,919	885,517
Deferred rent	59,579	59,579
Current liabilities of discontinued operations (Note 7)		2,765,648
Total current liabilities	3,311,370	5,515,113
Long-term deferred rent	620,864	629,568
Liabilities of discontinued operations, net (Note 7)		6,346,924
Total liabilities	$ 3,932,234	$ 12,491,605
Commitments and contingencies (Note 3)
Stockholders' equity
Preferred Stock, par value $.0001; 10,000,000 shares authorized; none issued
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding - 52,016,432 (unaudited) in 2016 and 51,998,306 in 2015	$ 5,202	$ 5,200
Additional paid-in capital	158,687,250	170,999,410
Advances to stockholders	(90,640)	(90,640)
Accumulated deficit	(140,679,601)	(133,914,812)
Total Ampio stockholders' equity	17,922,211	36,999,158
Non-controlling interests of discontinued operations		927,830
Total stockholders' equity	17,922,211	37,926,988
Total liabilities and stockholders' equity	$ 21,854,445	$ 50,418,593

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred Stock, par value	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	52,016,432	51,998,306
Common Stock, shares outstanding	52,016,432	51,998,306

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating expenses
Research and development	$ 4,275,577	$ 3,884,488
Research and development - related party (Note 6)	35,950	35,950
General and administrative	2,110,896	1,873,270
Total operating expenses	6,422,423	5,793,708
Other income (expense)
Interest income	10,154	44,477
Loss from equity investment in Aytu BioScience, Inc.	(352,520)
Total other (expense) income	(342,366)	44,477
Net loss from continuing operations	(6,764,789)	(5,749,231)
Loss from discontinued operations (Note 7)		(1,842,189)
Net loss	(6,764,789)	(7,591,420)
Net loss applicable to non-controlling interests		307,837
Net loss applicable to Ampio	$ (6,764,789)	$ (7,283,583)
Basic and diluted Ampio net loss per common share
From continuing operations	$ (0.13)	$ (0.11)
From discontinued operations and non-controlling interests		(0.03)
Net loss per share applicable to Ampio	$ (0.13)	$ (0.14)
Weighted average number of Ampio common shares outstanding	52,016,034	51,981,340

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) (unaudited) - 3 months ended Mar. 31, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Advances to Stockholders [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]
Beginning Balance at Dec. 31, 2015	$ 37,926,988	$ 5,200	$ 170,999,410	$ (90,640)	$ (133,914,812)	$ 927,830
Beginning Balance, shares at Dec. 31, 2015		51,998,306
Common stock issued for services	60,000	$ 2	59,998
Common stock issued for services, shares		18,126
Distribution to stockholders	(13,018,687)		(13,018,687)
Warrant modification	36,643		36,643
Stock-based compensation	609,886		609,886
Net loss	(6,764,789)				(6,764,789)
Changes in non-controlling interests	(927,830)					$ (927,830)
Ending Balance at Mar. 31, 2016	$ 17,922,211	$ 5,202	$ 158,687,250	$ (90,640)	$ (140,679,601)
Ending Balance, shares at Mar. 31, 2016		52,016,432

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (6,764,789)	$ (7,591,420)
Losses in equity investment in Aytu BioScience, Inc.	352,520
Stock-based compensation and warrant modification	646,529	1,144,803
Depreciation and amortization	305,533	206,426
Amortization of prepaid research and development - related party (Note 6)	35,950	35,950
Common stock issued for services	60,000	30,000
Adjustments to reconcile net loss to net cash used in operating activities
(Increase) decrease in prepaid expenses	(111,135)	418,456
Decrease in accounts receivable	38,451
Increase (decrease) in accounts payable	406,505	(2,017,840)
Decrease in deferred rent	(8,704)	(6,286)
Increase in accrued compensation	155,402	297,227
Net cash used in operating activities - continuing operations	(4,883,738)	(7,482,684)
Net cash provided by operating activities - discontinued operations		476,546
Net cash used in operating activities	(4,883,738)	(7,006,138)
Cash flows used in investing activities
Purchase of fixed assets		(43,060)
Net cash used in investing activities - continuing operations		(43,060)
Net cash provided by investing activities - discontinued operations	0	0
Net cash provided by (used in) investing activities		(43,060)
Cash flows from financing activities
Net cash used in financing activities - continuing operations	0	0
Net cash provided by financing activities - discontinued operations	0	0
Net cash used in financing activities	0	0
Net change in cash and cash equivalents	(4,883,738)	(7,049,198)
Cash and cash equivalents at beginning of period	26,957,938	50,159,751
Cash and cash equivalents - Aytu BioScience, Inc. at beginning of period	(10,959,546)	160,905
Cash and cash equivalents at the beginning of period	15,998,392	50,320,656
Cash and cash equivalents at end of period	11,114,654	43,271,458
Non-cash transactions:
Distribution to stockholders	$ 13,018,687
Fixed asset purchases included in accounts payable		$ 44,612

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Note 1—Basis of Presentation These financial statements represent the financial statements of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”). Ampio is a biopharmaceutical company focused on primarily developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depleting available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. Ampio’s activities have been primarily related to research and development and raising capital and have not generated revenue to date. On January 4, 2016, Ampio completed the spin-off of Aytu BioScience, Inc. (“Aytu”) by distributing a majority of its shares of common stock of Aytu to the Ampio shareholders on a pro rata basis. This transaction changed Ampio’s ownership from 81.5% to 8.6% of Aytu’s outstanding shares on that date. Ampio believes it continues to have significant influence over Aytu subsequent to the spin-off due to the fact that Ampio’s Chief Executive Officer was Aytu’s only Board member until mid-January 2016 when he became one of three Aytu Board of Directors members. Therefore, Ampio has accounted for its remaining investment in Aytu based on the equity method of accounting. As of March 31, 2016 Ampio’s ownership in Aytu’s outstanding shares was 5.5% ( see Note 7 – Discontinued Operations Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation –Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition Measurement of Financial Assets and Financial Liabilities In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, Revenue from Contracts with Customers

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 2—Fixed Assets Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following: Estimated As of March 31, As of December 31, Useful Lives in years 2016 2015 Manufacturing Facility/Clean Room 8 $ 2,734,000 $ 2,734,000 Leasehold improvements 10 6,075,000 6,075,000 Office furniture and equipment 3 - 10 557,000 557,000 Lab equipment 5 -10 1,019,000 1,019,000 Less accumulated depreciation and accretion (1,503,000 ) (1,198,000 ) Fixed assets, net $ 8,882,000 $ 9,187,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 3—Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table: Remaining Total 2016 2017 2018 2019 2020 Thereafter Ampion supply agreement $ 5,100,000 $ — $ 2,550,000 $ 2,550,000 $ — $ — $ — Clinical research and trial obligations 1,738,000 1,705,000 33,000 — — — — Facility lease 2,851,000 224,000 306,000 316,000 326,000 335,000 1,344,000 Sponsored research agreement with related party 975,000 244,000 325,000 325,000 81,000 — — $ 10,664,000 $ 2,173,000 $ 3,214,000 $ 3,191,000 $ 407,000 $ 335,000 $ 1,344,000 Ampion Supply Agreement In October 2013, Ampio entered into an agreement to purchase human serum albumin, the starting raw material for the Company’s Ampion product. Under this agreement, the Company still has a remaining commitment of $5,100,000. Per an amendment to the original agreement, Ampio is not committed to purchase any human serum albumin during 2016 and has extended the agreement to 2018. Clinical Research and Trial Obligations In connection with current and recent clinical trials, as of March 31, 2016, Ampio has a remaining commitment of $1,738,000 on contracts related to the active Ampion clinical trial. Facility Lease On December 13, 2013, Ampio entered into a 125-month non-cancellable operating lease for new office space and the manufacturing facility effective May 1, 2014. The new lease has initial base rent of $23,000 per month, with the total base rent over the term of the lease of approximately $3.3 million and includes rent abatements and leasehold incentives. The Company recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows: Three Months Ended March 31, 2016 2015 Rent expense $ 73,000 $ 64,000 Sponsored Research Agreement with Related Party Ampio entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in September 2009. Under the terms of the Sponsored Research Agreement, Ampio is to provide personnel and pay for leased equipment. The Sponsored Research Agreement may be terminated without cause by either party on 180 days’ notice. As further noted in Note 6—Related Party Transactions, in March 2014, the Sponsored Research Agreement was extended through March 2019, including a “no termination” period through March 2017. In a subsequent addendum, the parties also agreed to increase the equivalent value of the personnel provided by Ampio from $264,000 to $325,000 per year.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Common Stock	Note 4—Common Stock Capital Stock At March 31, 2016 and December 31, 2015, Ampio had 52,016,432 and 51,998,306 common shares outstanding, respectively. As of these same dates, Ampio had no preferred shares outstanding. Ampio has 100.0 million shares of common stock authorized with a par value of $0.0001 per share and 10.0 million shares of preferred stock authorized with a par value of $0.0001 per share. Shelf Registration In December 2013, Ampio filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) to register Ampio common stock and warrants in an aggregate amount of up to $100.0 million for offering from time to time in the future, as well as 1.5 million shares of common stock available for sale by selling shareholders. The shelf registration was declared effective in January 2014 by the SEC. As a result of prior equity raises, approximately $86.3 million remains available under the Form S-3 as of March 31, 2016. Controlled Equity Offering In February 2016, Ampio entered into a Controlled Equity Offering SM Common Stock Issued for Services Ampio issued 18,126 and 7,998 shares valued at $60,000 and $30,000, respectively, for non-employee directors as part of their director fees for fiscal years 2016 and 2015, respectively.

Equity Instruments

Equity Instruments	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Instruments	Note 5—Equity Instruments Options In 2010, Ampio shareholders approved the adoption of a stock and option award plan (the “2010 Plan”), under which shares were reserved for future issuance under restricted stock awards, options, and other equity awards. The 2010 Plan permits grants of equity awards to employees, directors and consultants. The shareholders have approved a total of 11.7 million shares reserved for issuance under the 2010 plan. Ampio has computed the fair value of all options granted using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Ampio calculates its volatility assumption using the actual changes in the market value of its stock. Ampio has estimated a forfeiture rate of 5.3% based upon historical experience; this is an estimate of options granted that are expected to be forfeited or cancelled before becoming fully vested. Ampio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. During the three months ended March 31, 2016, Ampio granted 5,000 options at a price of $6.53 to a former employee to replace 5,000 options that were forfeited due to the spin-off of Aytu. The $6.53 price represented the fair market value on the original date of the grant. In January 2016, Aytu accelerated the vesting of 335,000 Aytu options to employees of Ampio. The Company recognized expense in the amount of $312,000 related to this modification during the quarter ended March 31, 2016. Ampio has computed the fair value of all options granted during the three months ended March 31, 2016 using the following assumptions: Expected volatility 124 % Risk free interest rate 0.61 % Expected term (years) 1.0 Dividend yield 0.0 % Ampio stock option activity is as follows: Number of Weighted Weighted Average Outstanding December 31, 2015 7,315,832 $ 3.71 6.58 Granted 5,000 $ 6.53 Exercised — $ — Forfeited — $ — Expired or Cancelled (5,000 ) $ 6.53 Outstanding March 31, 2016 7,315,832 $ 3.71 5.54 Exercisable at March 31, 2016 6,336,607 $ 3.71 5.22 Available for grant at March 31, 2016 2,971,647 Stock options outstanding and exercisable at March 31, 2016 are summarized in the table below: Range of Exercise Prices Number of Weighted Weighted Average $1.03 - $4.00 5,140,832 $ 2.38 5.28 $4.01 - $7.00 1,240,000 $ 6.17 5.64 $7.01 - $8.93 935,000 $ 7.73 6.83 7,315,832 $ 3.71 5.54 Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and selling, general and administrative expenses as set forth in the table below. Ampio determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation expense for the three months ended March 31, 2016 and 2015: Three Months Ended March 31, 2016 2015 Research and development expenses Stock options $ 90,000 $ 608,000 General and administrative expenses Common stock issued for services 60,000 30,000 Stock options 520,000 537,000 $ 670,000 $ 1,175,000 Unrecognized expense at March 31, 2016 $ 836,613 Weighted average remaining years to vest 0.25 Warrants Ampio issued warrants in conjunction with its senior convertible debentures, 2011 private placements and an underwritten public offering. A summary of all Ampio warrants is as follows: Number of Weighted Weighted Average Outstanding December 31, 2015 499,076 $ 3.24 1.19 Warrants exercised — $ — Outstanding March 31, 2016 499,076 $ 3.24 1.03 In March 2016, the Company modified 45,300 of its outstanding warrants which extended the expiration for an additional year from March 31, 2016 to March 31, 2017. The $37,000 expense related to this modification was recognized in the quarter ended March 31, 2016.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 6—Related Party Transactions Ampio entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio’s director and Chief Scientific Officer, Dr. Bar-Or, in September 2009, which has been amended six times with the last amendment occurring in January 2015. Under the amended terms of the research agreement, Ampio will provide personnel with an equivalent value of $325,000 per year. With the fifth amendment, Ampio also paid $725,000 in 2014 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet. In return, TRLLC will assign any intellectual property rights it develops on Ampio’s behalf under the research agreement and undertake additional activities to support Ampio’s commercial activities and business plan. This agreement is set to expire in March 2019 and cannot be terminated prior to March 2017. The Company has advances to one executive and three employees that were used to purchase stock in the Company when it was formed during 2010. These advances are non-interest bearing and due on demand and are classified as a reduction to stockholders’ equity. As of March 31, 2016 and December 31, 2015, advances of $91,000 to stockholders remained outstanding.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 7—Discontinued Operations On January, 4, 2016, the Company completed the spin-off of Aytu by distributing a majority of its shares of common stock of Aytu to the Ampio shareholders on a pro rata basis. The Aytu business has been included in Ampio’s financial results as discontinued operations for all periods presented. Please refer to Note 1 – Basis of Presentation For all periods presented, the operating results associated with the Aytu business have been reclassified into loss from discontinued operations in the condensed statement of operations. Due to the holiday on January 1, 2016, and January 2 nd rd Three Months Ended March 31, 2016 2015 Revenue $ — $ 23,829 Total operating expenses — (1,829,966 ) Interest (expense) — (36,052 ) Loss from discontinued operations $ — $ (1,842,189 ) Assets and liabilities of discontinued operations consisted of the following at December 31, 2015: December 31, 2015 Cash and cash equivalents $ 10,959,546 Prepaid expenses and other 1,644,674 Prepaid research and development - related party 121,983 Current assets of discontinued operations 12,726,203 Fixed assets, net 143,826 In-process research and development 7,500,000 Developed technology, customer contracts and trade names, net 2,909,583 Goodwill 221,000 Patents, net 593,382 Long-term portion of prepaid research and development - related party 274,463 Deposits 2,888 Other assets of discontinued operations 11,645,142 Assets of discontinued operations $ 24,371,345 Accounts payable $ 1,076,293 Primsol payable 1,111,057 Accrued compensation 492,584 Deferred revenue 85,714 Current liabilities of discontinued operations 2,765,648 Convertible promissory notes, net of unamortized discount of $253,448 4,921,552 Interest payable 161,988 Contingent consideration 687,685 Long-term deferred rent 11,694 Long-term deferred revenue 383,036 Warrant derivative liability 180,969 Liabilities of discontinued operations 6,346,924 Liabilities of discontinued operations $ 9,112,572

Litigation

Litigation	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Litigation	Note 8—Litigation As previously disclosed, on May 8, 2015 and May 14, 2015, purported stockholders of the Company brought two putative class action lawsuits in the United States District Court in the Central District of California, Napoli v. Ampio Pharmaceuticals, Inc., et al., Case No. 2:15-cv-03474-TJH and Stein v. Ampio Pharmaceuticals, Inc., et al., Case No. 2:15-cv-03640-TJH (the “Securities Class Actions”), alleging that Ampio and certain of its current and former officers violated federal securities laws by misrepresenting and/or omitting information regarding the STEP study. The cases were consolidated, and on February 8, 2016, plaintiffs filed a consolidated amended complaint alleging claims under Sections 10(b) and 20(a) and Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Sections 11 and 15 under the Securities Act of 1933 on behalf of a putative class of purchasers of common stock from January 13, 2014 through August 21, 2014, including purchasers in the Company’s offering on February 28, 2014. On April 8, 2016, Ampio and the other defendants moved to dismiss the consolidated amended complaint. The lawsuits seek unspecified damages, pre-judgment and post-judgment interest, and attorneys’ fees and costs. On August 6, 2015 and September 25, 2015, purported stockholders of the Company brought derivative actions in the United States District Court in the Central District of California, Oglina v. Macaluso et al., Case No. 2:15-cv-05970-TJH-PJW (“Oglina action”) and the Colorado state court in Denver, Loyd v. Giles et al., Case No. 2015CV33429 (“Loyd action”), alleging primarily that the directors and officers of Ampio breached their fiduciary duties because of their alleged misstatements and/or omissions regarding the STEP study. Pursuant to the parties’ stipulation, the United States District Court in the Central District of California has stayed the proceedings in the Oglina action at the present time in accordance with the terms of the parties’ stipulation. Pursuant to the parties’ stipulation, the Colorado state court in Denver has stayed the Loyd action at the present time in accordance with the terms of the parties’ stipulation. The Company believes these claims are without merit and intends to defend these lawsuits vigorously. The Company currently believes the likelihood of a loss contingency related to these matters is remote and, therefore, no provision for a loss contingency is required.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation –Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition Measurement of Financial Assets and Financial Liabilities In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, Revenue from Contracts with Customers

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following: Estimated As of March 31, As of December 31, Useful Lives in years 2016 2015 Manufacturing Facility/Clean Room 8 $ 2,734,000 $ 2,734,000 Leasehold improvements 10 6,075,000 6,075,000 Office furniture and equipment 3 - 10 557,000 557,000 Lab equipment 5 -10 1,019,000 1,019,000 Less accumulated depreciation and accretion (1,503,000 ) (1,198,000 ) Fixed assets, net $ 8,882,000 $ 9,187,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Summary of Commitments and Contingencies	Commitments and contingencies are described below and summarized by the following table: Remaining Total 2016 2017 2018 2019 2020 Thereafter Ampion supply agreement $ 5,100,000 $ — $ 2,550,000 $ 2,550,000 $ — $ — $ — Clinical research and trial obligations 1,738,000 1,705,000 33,000 — — — — Facility lease 2,851,000 224,000 306,000 316,000 326,000 335,000 1,344,000 Sponsored research agreement with related party 975,000 244,000 325,000 325,000 81,000 — — $ 10,664,000 $ 2,173,000 $ 3,214,000 $ 3,191,000 $ 407,000 $ 335,000 $ 1,344,000
Rent Expense	Rent expense for the respective periods is as follows: Three Months Ended March 31, 2016 2015 Rent expense $ 73,000 $ 64,000

Equity Instruments (Tables)

Equity Instruments (Tables)	3 Months Ended
	Mar. 31, 2016
Summary of Stock Options Outstanding and Exercisable	Stock options outstanding and exercisable at March 31, 2016 are summarized in the table below: Range of Exercise Prices Number of Weighted Weighted Average $1.03 - $4.00 5,140,832 $ 2.38 5.28 $4.01 - $7.00 1,240,000 $ 6.17 5.64 $7.01 - $8.93 935,000 $ 7.73 6.83 7,315,832 $ 3.71 5.54
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense for the three months ended March 31, 2016 and 2015: Three Months Ended March 31, 2016 2015 Research and development expenses Stock options $ 90,000 $ 608,000 General and administrative expenses Common stock issued for services 60,000 30,000 Stock options 520,000 537,000 $ 670,000 $ 1,175,000 Unrecognized expense at March 31, 2016 $ 836,613 Weighted average remaining years to vest 0.25
Warrants Issued in Conjunction with its Senior Convertible Debentures	Warrants Ampio issued warrants in conjunction with its senior convertible debentures, 2011 private placements and an underwritten public offering. A summary of all Ampio warrants is as follows: Number of Weighted Weighted Average Outstanding December 31, 2015 499,076 $ 3.24 1.19 Warrants exercised — $ — Outstanding March 31, 2016 499,076 $ 3.24 1.03
Ampio [Member]
Assumptions Used in Computing Fair Value of All Options Granted	Ampio has computed the fair value of all options granted during the three months ended March 31, 2016 using the following assumptions: Expected volatility 124 % Risk free interest rate 0.61 % Expected term (years) 1.0 Dividend yield 0.0 %
Stock Option Activity	Ampio stock option activity is as follows: Number of Weighted Weighted Average Outstanding December 31, 2015 7,315,832 $ 3.71 6.58 Granted 5,000 $ 6.53 Exercised — $ — Forfeited — $ — Expired or Cancelled (5,000 ) $ 6.53 Outstanding March 31, 2016 7,315,832 $ 3.71 5.54 Exercisable at March 31, 2016 6,336,607 $ 3.71 5.22 Available for grant at March 31, 2016 2,971,647

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Summary of Assets and Liabilities of Discontinued Operations	The following table provides a summary of Aytu amounts included in discontinued operations: Three Months Ended March 31, 2016 2015 Revenue $ — $ 23,829 Total operating expenses — (1,829,966 ) Interest (expense) — (36,052 ) Loss from discontinued operations $ — $ (1,842,189 ) Assets and liabilities of discontinued operations consisted of the following at December 31, 2015: December 31, 2015 Cash and cash equivalents $ 10,959,546 Prepaid expenses and other 1,644,674 Prepaid research and development - related party 121,983 Current assets of discontinued operations 12,726,203 Fixed assets, net 143,826 In-process research and development 7,500,000 Developed technology, customer contracts and trade names, net 2,909,583 Goodwill 221,000 Patents, net 593,382 Long-term portion of prepaid research and development - related party 274,463 Deposits 2,888 Other assets of discontinued operations 11,645,142 Assets of discontinued operations $ 24,371,345 Accounts payable $ 1,076,293 Primsol payable 1,111,057 Accrued compensation 492,584 Deferred revenue 85,714 Current liabilities of discontinued operations 2,765,648 Convertible promissory notes, net of unamortized discount of $253,448 4,921,552 Interest payable 161,988 Contingent consideration 687,685 Long-term deferred rent 11,694 Long-term deferred revenue 383,036 Warrant derivative liability 180,969 Liabilities of discontinued operations 6,346,924 Liabilities of discontinued operations $ 9,112,572

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - Aytu [Member]	Mar. 31, 2016	Jan. 04, 2016
Basis of Presentation and Business [Line Items]
Ownership percentage by parent	5.50%
Maximum [Member]
Basis of Presentation and Business [Line Items]
Non controlling interest, ownership percentage by parent		81.50%
Minimum [Member]
Basis of Presentation and Business [Line Items]
Non controlling interest, ownership percentage by parent		8.60%

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and accretion	$ (1,503,000)	$ (1,198,000)
Fixed assets, net	$ 8,882,087	9,187,620
Manufacturing Facility/Clean Room [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Fixed assets, gross	$ 2,734,000	2,734,000
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Fixed assets, gross	$ 6,075,000	6,075,000
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 557,000	557,000
Office furniture and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office furniture and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 1,019,000	$ 1,019,000
Lab equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Lab equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years

Commitments and Contingencies -

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)	Mar. 31, 2016USD ($)
Commitment And Contingencies [Line Items]
Total	$ 10,664,000
2,016	2,173,000
2,017	3,214,000
2,018	3,191,000
2,019	407,000
2,020	335,000
Thereafter	1,344,000
Ampion Supply Agreement [Member]
Commitment And Contingencies [Line Items]
Total	5,100,000
2,017	2,550,000
2,018	2,550,000
Clinical Research and Trial Obligations [Member]
Commitment And Contingencies [Line Items]
Total	1,738,000
2,016	1,705,000
2,017	33,000
Sponsored Research Agreement With Related Party [Member]
Commitment And Contingencies [Line Items]
Total	975,000
2,016	244,000
2,017	325,000
2,018	325,000
2,019	81,000
Facility Lease [Member]
Commitment And Contingencies [Line Items]
Total	2,851,000
2,016	224,000
2,017	306,000
2,018	316,000
2,019	326,000
2,020	335,000
Thereafter	$ 1,344,000

Commitments and Contingencies23

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 30, 2014
Commitments and Contingencies [Line Items]
Contractual obligation	$ 10,664,000
Equipment lease payments net	$ 325,000	$ 264,000
Newly Leased Office Space and Manufacturing Facility [Member]
Commitments and Contingencies [Line Items]
Non-cancellable operating lease period	125 months
Non-cancellable operating lease initiation date	Dec. 13, 2013
Non-cancellable operating lease effective date	May 1, 2014
Lease initial base rent per month	$ 23,000
Total base rent over the term of the lease	3,300,000
Sponsored Research Agreement With Related Party [Member]
Commitments and Contingencies [Line Items]
Contractual obligation	$ 975,000
Lease expiration date	2019-03
Sponsored Research Agreement termination notice period	180 days
Ampion Study Production [Member] | Clinical Research Obligations [Member]
Commitments and Contingencies [Line Items]
Commitment remain under terms of clinical research agreement	$ 1,738,000
Ampion Supply Agreement [Member]
Commitments and Contingencies [Line Items]
Contractual obligation	$ 5,100,000

Commitments and Contingencies24

Commitments and Contingencies - Rent Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 73,000	$ 64,000

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2016	Dec. 31, 2015	Feb. 29, 2016
Components Of Common Stock [Line Items]
Common Stock, shares outstanding		52,016,432	51,998,306
Common Stock, shares authorized		100,000,000	100,000,000
Common Stock, par value		$ 0.0001	$ 0.0001
Preferred Stock, shares authorized		10,000,000	10,000,000
Preferred Stock, par value		$ 0.0001	$ 0.0001
Remaining common stocks and warrants under shelf registration		$ 86,300,000
Maximum aggregate offering price of equity securities				$ 25,000,000
Non Employee Directors [Member] | Common Stock [Member]
Components Of Common Stock [Line Items]
Issuance of common stock for services, shares		18,126	7,998
Issuance of common stock for services		$ 60,000	$ 30,000
Shelf Registration [Member]
Components Of Common Stock [Line Items]
Common stock and warrants	$ 100,000,000
Common stock to be sold by directors and management in future public offerings	1,500,000
Agreement [Member]
Components Of Common Stock [Line Items]
Percentage of commission				3.00%
Gross proceeds from issuance of common stock		$ 0

Equity Instruments - Additional

Equity Instruments - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeiture rate		5.30%
Number of option, Granted		5,000
Stock options exercise price		$ 6.53
Warrants Outstanding		499,076	499,076
Aytu [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested	335,000
Share based compensation		$ 312,000
Aytu [Member] | Spinoff [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Forfeited		5,000
Ampio March 2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance				11,700,000
Modified Outstanding Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation		$ 37,000
Warrants Outstanding		45,300

Equity Instruments - Assumption

Equity Instruments - Assumptions Used in Computing Fair Value of All Options Granted (Detail)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected volatility	124.00%
Risk free interest rate	0.61%
Expected term (years)	1 year
Dividend yield	0.00%

Equity Instruments - Stock Opti

Equity Instruments - Stock Option Activity (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	5,000
Weighted Average Exercise Price, Granted	$ 6.53
Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	7,315,832
Number of Options, Granted	5,000
Number of Options, Exercised	0
Number of Options, Forfeited/Cancelled	0
Number of Options, Expired or Cancelled	(5,000)
Number of Options, Ending Balance	7,315,832	7,315,832
Number of Options, Exercisable	6,336,607
Number of Options, Available for grant	2,971,647
Weighted Average Exercise Price, Beginning Balance	$ 3.71
Weighted Average Exercise Price, Granted	6.53
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Forfeited/Cancelled	0
Weighted Average Exercise Price, Expired or Cancelled	6.53
Weighted Average Exercise Price, Ending Balance	3.71	$ 3.71
Weighted average exercise price, Exercisable	$ 3.71
Weighted Average Remaining Contractual Life, Outstanding	5 years 6 months 15 days	6 years 6 months 29 days
Weighted Average Remaining Contractual Life, Exercisable	5 years 2 months 19 days

Equity Instruments - Summary of

Equity Instruments - Summary of Stock Options Outstanding and Exercisable (Detail)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding and Exercisable | shares	7,315,832
Weighted Average Exercise Price	$ 3.71
Weighted Average Remaining Contractual Lives	5 years 6 months 15 days
$1.03 - $4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$ 1.03
Range of Exercise Prices Upper	$ 4
Number of Options Outstanding and Exercisable | shares	5,140,832
Weighted Average Exercise Price	$ 2.38
Weighted Average Remaining Contractual Lives	5 years 3 months 11 days
$4.01 - $7.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$ 4.01
Range of Exercise Prices Upper	$ 7
Number of Options Outstanding and Exercisable | shares	1,240,000
Weighted Average Exercise Price	$ 6.17
Weighted Average Remaining Contractual Lives	5 years 7 months 21 days
$7.01 - $8.93 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$ 7.01
Range of Exercise Prices Upper	$ 8.93
Number of Options Outstanding and Exercisable | shares	935,000
Weighted Average Exercise Price	$ 7.73
Weighted Average Remaining Contractual Lives	6 years 9 months 29 days

Equity Instruments - Summary 30

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2016	$ 836,613
Weighted average remaining years to vest	3 months
Research and Development Expenses [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 90,000	$ 608,000
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	670,000	1,175,000
General and Administrative Expenses [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	520,000	537,000
General and Administrative Expenses [Member] | Common Stock Issued for Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 60,000	$ 30,000

Equity Instruments - Warrants I

Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	499,076
Number of Warrants Outstanding, Ending Balance	499,076	499,076
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 3.24
Weighted Average Exercise Price, Outstanding Ending Balance	$ 3.24	$ 3.24
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	1 year 11 days	1 year 2 months 9 days
Registered Direct Placement One [Member]
Number of Warrants Outstanding
Number of Warrants, Exercised	0
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Warrants Exercised	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Mar. 30, 2014
Related Party Transaction [Line Items]
Equipment lease payments net	$ 325,000		$ 264,000
Trauma Research LLC [Member] | First Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Equipment lease payments net	325,000
Consideration for services related to research and development	$ 725,000
Contract term	60 months 15 days
Lease expiration date	2019-03
Stockholders [Member]
Related Party Transaction [Line Items]
Advance to stockholders	$ 91,000	$ 91,000

Discontinued Operations - Summa

Discontinued Operations - Summary of Aytu Amounts Included in Discontinued Operations (Detail)	3 Months Ended
	Mar. 31, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations	$ (1,842,189)
Aytu [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	23,829
Total operating expenses	(1,829,966)
Interest (expense)	(36,052)
Loss from discontinued operations	$ (1,842,189)

Discontinued Operations - Sum34

Discontinued Operations - Summary of Assets and Liabilities of Discontinued Operations (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Cash and cash equivalents	$ (10,959,546)	$ 10,959,546	$ 160,905
Prepaid expenses and other		1,644,674
Prepaid research and development - related party		121,983
Current assets of discontinued operations		12,726,203
Fixed assets, net		143,826
In-process research and development		7,500,000
Developed technology, customer contracts and trade names, net		2,909,583
Goodwill		221,000
Patents, net		593,382
Long-term portion of prepaid research and development - related party		274,463
Deposits		2,888
Other assets of discontinued operations		11,645,142
Assets of discontinued operations		24,371,345
Accounts payable		1,076,293
Primsol payable		1,111,057
Accrued compensation		492,584
Deferred revenue		85,714
Current liabilities of discontinued operations		2,765,648
Convertible promissory notes, net of unamortized discount of $253,448		4,921,552
Interest payable		161,988
Contingent consideration		687,685
Long-term deferred rent		11,694
Long-term deferred revenue		383,036
Warrant derivative liability		180,969
Liabilities of discontinued operations		6,346,924
Liabilities of discontinued operations		$ 9,112,572

Discontinued Operations - Sum35

Discontinued Operations - Summary of Assets and Liabilities of Discontinued Operations (Parenthetical) (Detail)	Dec. 31, 2015USD ($)
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Net unamortized discount	$ 253,448

Litigation - Additional Informa

Litigation - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015Lawsuits
Commitments and Contingencies Disclosure [Abstract]
Number of class action lawsuits	2